Market Cap 759.91M
Revenue (ttm) 105.76M
Net Income (ttm) 12.09M
EPS (ttm) N/A
PE Ratio 153.80
Forward PE 26.07
Profit Margin 11.43%
Debt to Equity Ratio 0.00
Volume 81,400
Avg Vol 92,842
Day's Range N/A - N/A
Shares Out 96.31M
Stochastic %K 47%
Beta 1.86
Analysts Strong Sell
Price Target $19.00

Company Profile

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the...

Industry: Biotechnology
Sector: Healthcare
Phone: 619 949 3681
Address:
12770 High Bluff Drive, Suite 150, San Diego, United States
NetworkNewsWire
NetworkNewsWire Sep. 9 at 3:57 PM
BioMedNewsBreaks — $GYRE Advances Toward China Approval and Expands Clinical Pipeline With Hydronidone https://ibn.fm/9wCTA
0 · Reply
Channelchek
Channelchek Sep. 9 at 1:50 PM
Noble Capital Markets Research Report: Gyre Therapeutics, Inc ($GYRE) – Positioned To End YE2025 With Strong Products and Pipeline Development Gyre Has Made Strong YTD Progress. Gyre has made significant progress during the first three quarters of FY2025 that we believe positions the company for a strong year-end. These developments include continued sales growth from two products introduced in 1H25, an application for Hydronidone approval in China, and the start of a Phase 2 clinical trial for Hydronidone in the US. The company also announced the appointment of Dr. Han Ying as the new CEO, a member of the Board of Directors since January 2025. Read more: https://www.channelchek.com/news-channel/gyre-therapeutics-inc-gyre-positioned-to-end-ye2025-with-strong-products-and-pipeline-development
0 · Reply
Arya3t
Arya3t Aug. 31 at 2:57 AM
HuiopkloiuytrewQA $GYRE
0 · Reply
MalwareOfMarkets
MalwareOfMarkets Aug. 29 at 4:12 PM
$GYRE god damm waineright buy rating dropping now
0 · Reply
JarvisFlow
JarvisFlow Aug. 26 at 11:30 AM
HC Wainwright & Co. updates rating for Gyre Therapeutics ( $GYRE ) to Buy, target set at 18.
0 · Reply
MalwareOfMarkets
MalwareOfMarkets Aug. 13 at 10:45 PM
$GYRE and 8.27
0 · Reply
MalwareOfMarkets
MalwareOfMarkets Aug. 7 at 3:35 PM
$GYRE now 7.27
0 · Reply
MalwareOfMarkets
MalwareOfMarkets Aug. 1 at 7:45 PM
$GYRE now 666 lucky number?
0 · Reply
Slowhorses
Slowhorses Jul. 23 at 8:59 PM
$ALAR or $GYRE or $ SEMR ??? Any thoughts please which one to go ?
1 · Reply
BrielleX_619
BrielleX_619 Jul. 9 at 1:49 PM
$GYRE ⁨WKSP: U.S. factory ✅ 50%+ prod growth ✅ Doubling margins ✅ Nano-grid + solar Q3 rollout ✅ 1K-truck federal pilot ✅ No China exposure 🔥EYES ON $7+⁩
0 · Reply
Latest News on GYRE
NetworkNewsWire
NetworkNewsWire Sep. 9 at 3:57 PM
BioMedNewsBreaks — $GYRE Advances Toward China Approval and Expands Clinical Pipeline With Hydronidone https://ibn.fm/9wCTA
0 · Reply
Channelchek
Channelchek Sep. 9 at 1:50 PM
Noble Capital Markets Research Report: Gyre Therapeutics, Inc ($GYRE) – Positioned To End YE2025 With Strong Products and Pipeline Development Gyre Has Made Strong YTD Progress. Gyre has made significant progress during the first three quarters of FY2025 that we believe positions the company for a strong year-end. These developments include continued sales growth from two products introduced in 1H25, an application for Hydronidone approval in China, and the start of a Phase 2 clinical trial for Hydronidone in the US. The company also announced the appointment of Dr. Han Ying as the new CEO, a member of the Board of Directors since January 2025. Read more: https://www.channelchek.com/news-channel/gyre-therapeutics-inc-gyre-positioned-to-end-ye2025-with-strong-products-and-pipeline-development
0 · Reply
Arya3t
Arya3t Aug. 31 at 2:57 AM
HuiopkloiuytrewQA $GYRE
0 · Reply
MalwareOfMarkets
MalwareOfMarkets Aug. 29 at 4:12 PM
$GYRE god damm waineright buy rating dropping now
0 · Reply
JarvisFlow
JarvisFlow Aug. 26 at 11:30 AM
HC Wainwright & Co. updates rating for Gyre Therapeutics ( $GYRE ) to Buy, target set at 18.
0 · Reply
MalwareOfMarkets
MalwareOfMarkets Aug. 13 at 10:45 PM
$GYRE and 8.27
0 · Reply
MalwareOfMarkets
MalwareOfMarkets Aug. 7 at 3:35 PM
$GYRE now 7.27
0 · Reply
MalwareOfMarkets
MalwareOfMarkets Aug. 1 at 7:45 PM
$GYRE now 666 lucky number?
0 · Reply
Slowhorses
Slowhorses Jul. 23 at 8:59 PM
$ALAR or $GYRE or $ SEMR ??? Any thoughts please which one to go ?
1 · Reply
BrielleX_619
BrielleX_619 Jul. 9 at 1:49 PM
$GYRE ⁨WKSP: U.S. factory ✅ 50%+ prod growth ✅ Doubling margins ✅ Nano-grid + solar Q3 rollout ✅ 1K-truck federal pilot ✅ No China exposure 🔥EYES ON $7+⁩
0 · Reply
Ayed91
Ayed91 Jun. 21 at 1:52 PM
0 · Reply
topstockalerts
topstockalerts Jun. 17 at 1:45 PM
$GYRE not a bad place for a swing idea 💡💡💡
0 · Reply
Razz_FluidX2
Razz_FluidX2 Jun. 17 at 12:42 PM
0 · Reply
CyrusLopez5
CyrusLopez5 Jun. 16 at 7:49 PM
$AMD $BTC.X $XRP.X $GYRE Analyst price target for today🚀 https://lked.in/options-chat-live
0 · Reply
TwongStocks
TwongStocks Jun. 16 at 12:34 PM
All seven NASDAQ stocks with a RS are being unhalted at 9:00am ET $GCTK 1 for 60. Will reduce outstanding shares from approx 32,541,327 to approx 542,356. $NCI 1 for 5. Will reduce ordinary shares from approx 20.32m to approx 4.064m. $GLYC 1for 100. RS + Merger with Crescent Biopharma. The RS will reduce GLYC ousttanding shares from approx 64.5m to approx 645k. GLYC will then effect the merger with Crescent Bio, changing the ticker to from GLYC to $GYRE. Following the closing of the Merger, the combined company’s total outstanding common stock is expected to be approximately 14.8m shares.
1 · Reply
TwongStocks
TwongStocks Jun. 13 at 8:51 PM
Monday reverse split preview Part 2. $GCTK 1 for 60. Will reduce outstanding shares from approx 32,541,327 to approx 542,356. $NCI 1 for 5. Will reduce ordinary shares from approx 20.32m to approx 4.064m. $GLYC 1for 100. RS + Merger with Crescent Biopharma. The RS will reduce GLYC ousttanding shares from approx 64.5m to approx 645k. GLYC will then effect the merger with Crescent Bio, changing the ticker to from GLYC to $GYRE. Following the closing of the Merger, the combined company’s total outstanding common stock is expected to be approximately 14.8m shares.
1 · Reply
PenkeTrading
PenkeTrading Jun. 12 at 2:34 AM
I found you a Bearish Engulfing Candle Pattern on the daily chart of Gyre Therapeutics Inc.. $GYRE #Gyre #BearishEngulfingCandle #NASDAQ
0 · Reply
jdlman
jdlman Jun. 10 at 4:38 PM
$GYRE why is this scrolling up? Any news ?
0 · Reply
Magic8BallResponse
Magic8BallResponse Jun. 10 at 12:43 PM
$GLYC Need to see where $GYRE opens
0 · Reply
ZacksResearch
ZacksResearch Jun. 6 at 1:33 PM
$GLYC stockholders just approved a 1-for-100 reverse split and a full-on merger 🚨 🧬 GlycoMimetics is merging with Crescent Biopharma and rebranding to "Crescent Biopharma, Inc." with ticker $GYRE 📉 Outstanding shares dropping from 64.5M to just 0.6M 🔁 New shares expected to begin trading June 16 on a post-split basis Massive reset in the works — dilution risk out, fresh story in. See the complete stock outlook here👉 https://www.zacks.com/stock/quote/GLYC?cid=sm-stocktwits-0-quote_overview-oc&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC
0 · Reply
Jutski_bipolar
Jutski_bipolar Jun. 2 at 8:54 PM
$GYRE dog 🐕 share
0 · Reply